Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Original Paper

Role for SUR2A in Coupling Cardiac KATP Channels to Caveolin-3

Sun W.1,2 · Hu K.1

Author affiliations

1Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH,2Department of Molecular Biology, Norman Bethune College of Medical Sciences, Jilin University, Changchun, China

Corresponding Author

Keli Hu, MD, Ph.D.

530 Parks Hall, Division of Pharmacology, College of Pharmacy

500 West 12th Avenue, The Ohio State University

Columbus, OH, 43210 (USA)

Tel. +1614-292-5433, Fax: +1614-292-9083, E-Mail hu.175@osu.edu

Related Articles for ""

Cell Physiol Biochem 2010;25:409–418

Do you have an account?

Login Information

Contact Information

By signing up for MyKarger you will automatically participate in our year-End raffle.
If you Then Do Not wish To participate, please uncheck the following box.

Yes, I wish To participate In the year-End raffle And Get the chance To win some Of our most interesting books, And other attractive prizes.

I have read the Karger Terms and Conditions and agree.


ATP-sensitive K+ channels in the heart are localized in the caveolae. However, little is known about the molecular mechanism underlying the caveolar targeting of those ion channels. The present study was designed to explore the molecular compositions involved in the interaction between cardiac KATP channels and caveolin-3. The HA-tagged wild-type (Kir6.2/SUR2A) or mutant KATP channel (Kir6.2C4A or Kir6.2Δ36) subunits were transiently transfected into COS-7 cells with or without caveolin-3. Both Kir6.2C4A and Kir6.2Δ36 are able to form tetrameric Kir6.2 channels on the cell membrane without SUR subunit. We demonstrated that caveolin-3 co-immunopreciptiated Kir6.2 in COS-7 cells transfected with Kir6.2/SUR2A/caveolin-3, whereas Kir6.2 was not detected in the caveolin-3 immunoprecipitates in cells transfected with either caveolin-3 or Kir6.2/SUR2A alone. In cells transfected with Kir6.2C4A/caveolin-3, Kir6.2C4A was detected with anti-HA antibody but at a significantly lower level in the caveolin-3 immunoprecipitates when compared with Kir6.2 detected in cells transfected with the Kir6.2/SUR2A/caveolin-3. Kir6.2C4A was not co-immunoprecipitated with caveolin-3 in cells transfected with caveolin-3 or Kir6.2C4A alone. The application of caveolin-3 scaffolding domain peptide, corresponding to amino acid residues 55-74 of caveolin-3, largely blocked the co-immunoprecipitation of caveolin-3 and Kir6.2/SUR2A octameric channels but did not prevent the co-immunoprecipitation of caveolin-3 and the Kir6.2 tetrameric channels. Disrupting caveolae with methyl-β-cyclodextrin significantly attenuated association of tetrameric Kir6.2 channels with caveolin-3. Immunofluorescence microscopy revealed that a higher percentage of cells showed significant colocalization of caveolin-3 with Kir6.2 than colocalization of caveolin-3 with Kir6.2C4A or Kir6.2Δ36. We further confirmed that in adult rat cardiac myocytes the association of endogenous octameric KATP channels with caveolin-3 was largely prevented by caveolin-3 scaffolding domain peptide but not control peptide. We concluded that SUR2A is important for coupling cardiac KATP channels to caveolin-3, possibly through the caveolin-3 scaffolding domain.

© 2010 S. Karger AG, Basel

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Accepted: December 09, 2009
Published online: March 23, 2010
Issue release date: March 2010

Number of Print Pages: 10
Number of Figures: 0
Number of Tables: 0

ISSN: 1015-8987 (Print)
eISSN: 1421-9778 (Online)

For additional information: https://www.karger.com/CPB

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.